Payment overview · 2025
General Payments
$21.23
1 reported records · 1 companies
Healthcare provider profile · identity verified
Emmet Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ESCONDIDO, CA · NPI 1558326801
Verified facts
What the public records show
CMS Open Payments records show Emmet Lee, M.D. received $21.23 in general payments during 2025 across 1 reported records.
ACADIA Pharmaceuticals Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nuplazid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.23 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $21.23 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $21.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 498 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 74 |
| Eliquis | Apixaban | 274 | 38 |
| Gabapentin | Gabapentin | 240 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 52 |
| Omeprazole | Omeprazole | 224 | 36 |
| Mirtazapine | Mirtazapine | 203 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 33 |
| Losartan Potassium | Losartan Potassium | 184 | 33 |
| Metformin Hcl | Metformin Hcl | 182 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 30 |
| Xarelto | Rivaroxaban | 157 | suppressed |
| Potassium Chloride | Potassium Chloride | 150 | 28 |
| Trazodone Hcl | Trazodone Hcl | 144 | 29 |
| Jardiance | Empagliflozin | 135 | 13 |
| Sertraline Hcl | Sertraline Hcl | 134 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 19 |
| Lisinopril | Lisinopril | 124 | 25 |
| Tramadol Hcl | Tramadol Hcl | 113 | 27 |
| Donepezil Hcl | Donepezil Hcl | 101 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 13 |
| Levetiracetam | Levetiracetam | 89 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 87 | 15 |
| Finasteride | Finasteride | 82 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 77 | 12 |
| Memantine Hcl | Memantine Hcl | 75 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 14 |
| Myrbetriq | Mirabegron | 73 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 12 |
| Latanoprost | Latanoprost | 64 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 31 |
| Simvastatin | Simvastatin | 59 | 11 |
| Carvedilol | Carvedilol | 56 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Famotidine | Famotidine | 52 | 22 |
| Glimepiride | Glimepiride | 51 | suppressed |
| Lorazepam | Lorazepam | 51 | 15 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 47 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 20 |
| Spironolactone | Spironolactone | 40 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Lactulose | Lactulose | 38 | 14 |
| Humulin N | Insulin Nph Human Isophane | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Humulin R | Insulin Regular, Human | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Procrit | Epoetin Alfa | 27 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 13 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Prednisone | Prednisone | 22 | 11 |
| Risperidone | Risperidone | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Exemestane | Exemestane | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Klor-Con M15 | Potassium Chloride | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21.23 · 1 records | ACADIA Pharmaceuticals Inc | NUPLAZID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error